Key result
Post-MI heart failure represents a distinct phenotype requiring early ACE inhibitors, beta-blockers, and MRAs.
Why the study?
Peculiarities in post-infarction heart failure pathophysiology have been increasingly understood, motivating a review of specific characteristics of this clinical phenotype to enable a more targeted clinical approach.
Discusses the pathophysiology and specific characteristics of post-infarction heart failure as a distinct clinical phenotype.
Answers are grounded in this paper and cite their sources.
Supports early phenotyping and GDMT in post-MI HF; leaves open prospective validation of this distinct phenotype.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Campos et al. (2023) conducted a review in Heart Failure After Acute Myocardial Infarction. Post-myocardial infarction heart failure represents a distinct clinical phenotype requiring early identification and targeted therapies with ACE inhibitors, beta-blockers, and mineralocorticoid antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: